


Accepted Manuscript

Effects of *Clostridium perfringens* iota toxin in the small intestine of mice

Leandro M. Redondo, Enzo A. Redondo, Gabriela C. Dailoff, Carlos L. Leiva, Juan M. Díaz-Carrasco, Octavio A. Bruzzone, Adriana Cangelosi, Patricia Geoghegan, Mariano E. Fernandez-Miyakawa



PII: S1075-9964(17)30151-8

DOI: [10.1016/j.anaerobe.2017.07.007](https://doi.org/10.1016/j.anaerobe.2017.07.007)

Reference: YANAE 1779

To appear in: *Anaerobe*

Received Date: 20 April 2017

Revised Date: 26 July 2017

Accepted Date: 27 July 2017

Please cite this article as: Redondo LM, Redondo EA, Dailoff GC, Leiva CL, Díaz-Carrasco JM, Bruzzone OA, Cangelosi A, Geoghegan P, Fernandez-Miyakawa ME, Effects of *Clostridium perfringens* iota toxin in the small intestine of mice, *Anaerobe* (2017), doi: 10.1016/j.anaerobe.2017.07.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Effects of *Clostridium perfringens* iota toxin in the small intestine of mice.**

- 2 Leandro M. Redondo ^{a, c} redondo.leandro@inta.gob.ar
3 Enzo A. Redondo ^{a, c} redondo.enzo@inta.gob.ar
4 Gabriela C. Dailoff ^{a, c} dailoff.gabriela@inta.gob.ar
5 Carlos L. Leiva ^{a, c} leiva.carlos@inta.gob.ar
6 Juan M Díaz-Carrasco ^{a, c} diazcarrasco.j@inta.gob.ar
7 Octavio A. Bruzzone ^{b, c} bruzzone.octavio@inta.gob.ar
8 Adriana Cangelosi ^d acangelosi@anlis.gov.ar
9 Patricia Geoghegan ^d pgeoghegan@anlis.gov.ar
10 Mariano E. Fernandez-Miyakawa ^{a, c, *} fernandezmiyakawa.m@inta.gob.ar

11 ^a Instituto de Patobiología, Centro Nacional de Investigaciones Agropecuarias, Instituto
12 Nacional de Tecnología Agropecuaria, Calle Las Cabañas y Los Reseros s/n, Casilla de
13 Correo 25 (1712), Castelar, Buenos Aires, Argentina.

14 ^b EEA Bariloche, Instituto Nacional de Tecnología Agropecuaria, Modesta Victoria 4450
15 (8400), Bariloche, Río Negro, Argentina.

16 ^c Consejo Nacional de Investigaciones Científicas y Técnicas, Rivadavia 1917 (1033),
17 Ciudad Autónoma de Buenos Aires, Argentina.

18 ^d Centro Nacional de Control de Calidad de Biológicos, ANLIS “Dr. Carlos G. Malbrán”,
19 Av. Vélez Sarsfield 563 (C1282AFF), Buenos Aires, Argentina

20

21 ^{*}Corresponding author: M. E. Fernandez-Miyakawa.

22 Phone - Fax: 0054-11-46210443

23 Email: fernandezmiyakawa.m@inta.gob.ar

24

25 Abstract

26

27 Iota toxin is a binary toxin solely produced by *Clostridium perfringens* type E strains, and
28 is structurally related to CDT from *C. difficile* and CST from *C. spiroforme*. As type E
29 causes hemorrhagic enteritis in cattle, it is usually assumed that associated diseases are
30 mediated by iota toxin, although evidence in this regard has not been provided. In the
31 present report, iota toxin intestinal effects were evaluated *in vivo* using a mouse model.
32 Histological damage was observed in ileal loops treated with purified iota toxin after 4 h of
33 incubation. Luminal iota toxin induced fluid accumulation in the small intestine in a dose
34 dependent manner, as determined by the enteropooling and the intestinal loop assays. None
35 of these changes were observed in the large intestine. These results suggest that *C.*
36 *perfringens* iota toxin alters intestinal permeability, predominantly by inducing necrosis
37 and degenerative changes in the mucosal epithelium of the small intestine, as well as
38 changes in intestinal motility. The obtained results suggest a central role for iota toxin in
39 the pathogenesis of *C. perfringens* type E hemorrhagic enteritis, and contribute to remark
40 the importance of clostridial binary toxins in digestive diseases.

41

42

43 Keywords

44 Iota toxin, binary toxins, *Clostridium perfringens*, intestinal permeability, gastrointestinal
45 transit.

46

47

48

49 **1. Introduction**

50

51 *Clostridium perfringens* type E infection in domestic animals was first reported in the late
52 1940s [1]. *C. perfringens* type E has been described to produce hemorrhagic enteritis in
53 calves [2,3], cows [4], sheep [5] and goats [6]. Although these infections have generally
54 been considered a rare occurrence in ruminants, there are numerous reports suggesting that
55 type E isolates may account for approximately 5% of all *C. perfringens* isolates and that
56 could be also associated with 50% of fatal hemorrhagic enteritis in calves [3,7]. In rabbits,
57 like *C. spiroforme* infection [8], *C. perfringens* type E disease has been clinically
58 characterized by general loss of condition, diarrhea and characteristic hemorrhagic lesions
59 of the cecal serosa and mucosa, and eventually the distal ileum and proximal colon with
60 presence of watery mucoid content [8]. As *C. perfringens* type E strains are defined by the
61 production of iota toxin (ITX) [5], it is usually assumed that associated diseases are
62 mediated by ITX, although no definitive evidence in this regard has been provided. ITX
63 belongs to the family of binary actin ADP-ribosylating toxins [9]. Other members of this
64 toxin family are *C. difficile* transferase (CDT), *C. spiroforme* transferase (CST), *C.*
65 *botulinum* C2 toxin, and *Bacillus cereus/sphaericus* vegetative insecticidal proteins (VIP)
66 [10]. These actin ADP-ribosylating binary toxins are composed of two unlinked proteins,
67 an enzymatic component with ADP-ribosyltransferase activity and a binding component
68 which binds to the cell surface receptor [11,12] and facilitates the enzymatic component
69 entry to the cytosol [9].

70 Although cellular intoxication by ITX and binary toxins has been extensively studied
71 [9,11–13], information about intestinal alterations induced by ITX are scant and usually

72 limited to descriptions of natural cases of type E diseases [3,4,6]. Therefore, the current
73 work aims to examine the intestinal effects of ITX and to define the role of ITX in *C.*
74 *perfringens* type E infection, revealing new insights into *C. perfringens* type E enteritis
75 pathogenesis. Also, the results from this study suggest that the mouse is a useful animal
76 model to study type E and ITX pathogenesis *in vivo*.

77

78

79 **2. Materials and Methods.**

80

81 **2.1. Animals:**

82 Conventionally reared 20–25 g NHI Swiss outbred male mice were used. Animals were
83 housed in a light cycle, humidity and temperature controlled room. Studies presented here
84 were reviewed and approved by the institutional animal care and use committee (IACUC)
85 from the CICVyA-INTA, protocol 32/2011.

86

87 **2.2. Iota toxin:**

88 Iota toxin (ITX) was purified from a type E culture as described by Stiles [14]. The purity
89 of ITX was >95% as assessed by densitometry on 12% SDS/PAGE followed by Coomassie
90 Blue staining. Activity and synergistic effect of Ia and Ib were tested on Caco-2 cell
91 monolayers [15]. For *in vivo* assays, ITX concentration was expressed based on the activity
92 on cell monolayers as ITX units (U), which are defined as the reciprocal of the highest
93 dilution inducing cytopathic changes on cell monolayers. According to total protein
94 concentration and the results of cell cytotoxicity tests, it was possible to determine that 200
95 U/ml of ITX corresponded to a concentration of 1 µg/ml of Ia and 2 µg/ml of Ib.

96

97 2.3. Lethality of ITX in mice:

98 The intragastric (i. g.) or intravenous (i. v.) lethality of ITX was determined using groups of
99 4 mice each. Animals received two-fold dilutions of ITX in 1% peptone water. Before i. g.
100 challenge, mice were fasted overnight but allowed access to water until 2 h before the start
101 of the experiment. Groups of mice were inoculated by i. g. gavage with 0.5 ml of 1.5% PBS
102 NaHCO₃ containing purified ITX (50, 100, or 200 U/ml) or buffer solution without ITX.
103 Another set of mice were i. v. injected with a total volume of 0.5 ml of PBS containing
104 purified ITX (50, 100, or 200 U/ml) or buffer solution without ITX. All mice were
105 observed for up to 72 h to monitor lethality, which was defined as death or development of
106 significant respiratory or neurological signs. Mice showing significant respiratory or
107 neurological signs were immediately euthanized and included in lethal dosed fifty
108 (LD₅₀/ml) calculations [16].

109

110 2.4. Effects of ITX on mice intestinal loops.

111 **2.4.1. Mice intestinal loop test:** Mice were fasted during 18 h and deprived of water 2 h
112 before the experiments. Anesthesia was then induced by intraperitoneal (i. p.) injection of
113 100 mg/kg of ketamine and 5 mg/kg of diazepam. The abdomen of each mouse was
114 disinfected with povidone-iodine solution (Pervinox) immediately before surgery. A
115 midline laparotomy was performed, and the ileum or colon was exposed. Only one 2 cm
116 long intestinal loop was prepared in the ileum or the colon of each animal by a double
117 ligation. Care was taken to avoid overdistension of bowel loops and interference with the
118 blood supply, eliminating a possible ischemic component to the toxin-induced damage.
119 During surgery, the serosal surface of the loops was kept wet by frequent soaking with

120 normal saline solution. After injecting the inoculum, the abdominal incision was closed by
121 separate muscle and skin sutures. The surgical procedure lasted approximately 3 min per
122 animal. Mice were kept under anesthesia by periodic administration of ketamine-diazepam
123 mix until the end of the experiments, 4 h after inoculation, and euthanized by cervical
124 dislocation.

125 **2.4.2. Inoculum:** In all experiments, a 0.5 ml aliquot of a Ringer's solution containing
126 specified amounts of purified ITX was injected into each intestinal loop. For the dose-
127 response experiments a mixture containing Ringer's solution with 0, 100 or 200 U/ml of
128 purified ITX was injected into each loop. . Additional loops received an injection of
129 Ringer's solution containing 200 U/ml of purified ITX that had been pre-incubated for 30
130 min at room temperature with neutralizing mice anti-ITX polyclonal antibody or with anti-
131 ITX IgY [17]. The amount of both anti-ITX antibodies (mice and egg yolk) used was the
132 minimum amount that neutralize ITX cytopathic changes on Caco-2 cell monolayers.
133 Control loops were injected with ITX pre-incubated with antibodies obtained from pre-
134 immune sera of mice or laying hens.

135 **2.4.3. Histological analyses:** At the end of the experiments, intestinal loops were excised
136 and fixed by immersion in 10 % neutral buffered formalin at pH 7.2 for a minimum of 48 h,
137 after which they were dehydrated through graded alcohols to xylene and embedded in
138 paraffin wax. Samples were cut to obtain 4 μ m thick sections. Tissue sections were
139 prepared and stained either with hematoxylin and eosin (H/E) or used for
140 immunohistochemistry (IHC) and examined by optical microscopy.

141 **2.4.4. ITX immunohistochemistry:** Deparaffinized tissue sections were treated with 1%
142 hydrogen peroxide in methanol to block endogenous peroxidases, followed by heat-induced
143 antigen retrieval in 0.01 M citrate acid buffer (pH 6). After that, sections of intestines were

144 overlaid sequentially with an egg yolk polyclonal anti-ITX antibody (1/100, vol/vol), and
145 peroxidase labeled rabbit anti-egg yolk (1/100, vol/vol; Sigma Aldrich Co) for 1 h each.
146 Antibodies were diluted in PBS. Control sections were treated using the same buffer but
147 omitting the primary antibody. Finally, preparations were revealed with diaminobenzidine
148 and hydrogen peroxide solution (DAB cod K3468; DAKO) and observed by optical
149 microscopy.

150

151 **2.5. Effects of ITX on intraluminal fluid accumulation:**

152 **2.5.1. Enteropooling:** Mucosal transport of fluid was determined using the enteropooling
153 assay that evaluates the net accumulation of fluid in the lumen of the small intestine [19].
154 After 18 h of fasting and 2 h of water deprivation, mice were treated as follows. Groups of
155 6 mice were dosed i. g. with 0.2 ml of 200 U/ml of ITX in 1.5% PBS NaHCO₃ or buffer
156 solution without ITX. Mice in both groups were sacrificed 4 or 20 h later. The small
157 intestine of all mice was clamped at the pyloric sphincter and immediately before the
158 ileocaecal junction, and carefully removed from the abdomen. The small intestine length
159 (L) was measured and then weighed (W1), dried of fluid and reweighed (W2). The
160 difference between W1 and W2 divided by the length $[(W1-W2)/L]$ represents the
161 “enteropooling” in milligrams of fluid per centimeter of intestine, which is an indication of
162 intestinal fluid accumulation [18].

163 **2.5.2. Fluid accumulation in intestinal loops:** Mice intestinal loops in ileum and colon
164 were prepared as previously described (Section 2.4.1.). Purified ITX (200 and 100U/ml in
165 Ringer’s solution) or control (Ringer’s solution without ITX) was injected into each loop.
166 After inoculation, the incisions in the peritoneum, abdominal muscles and skin were closed.
167 Mice were kept under anesthesia by periodic administration of ketamine-diazepam mix

168 until the end of the experiments 4 h after inoculation, when they were killed by cervical
169 dislocation. Intestinal loops were excised and the weight and length of each loop was
170 measured. The net increase in the weight of the loop (in milligrams) was calculated as a
171 relation between the weight of the inoculated loop and the length (in centimeters) of the
172 loop [18].

173

174 **2.6. Effects of ITX on gastrointestinal transit:**

175 The animals were deprived of food for 18 h prior to gastrointestinal transit measurement
176 but allowed water ad libitum until 2 h before the experiments. Groups of 6 mice were dosed
177 i. g. with 0.2 ml of 200 U/ml of ITX in 1.5% PBS NaHCO₃ or 0.2 ml of buffer solution
178 without ITX. A charcoal meal (0.2 ml per mouse) containing a solution of 1.5% arabic gum
179 and 5% charcoal as a marker was given i. g. to conscious mice in ITX treated and control
180 groups. Thirty minutes later, the mice were euthanized by cervical dislocation. The
181 abdominal cavity was opened and the gastrointestinal tract was removed. The traveled
182 distance of the marker was measured and expressed as a percentage of the total length of
183 the small intestine from the pylorus to caecum and this percentage was used as a
184 measurement of gastrointestinal transit [19].

185

186 **2.7. Statistical analysis:**

187 A Bayesian approach was used [20]. For each of the measured variables, we tested the
188 effect of treatment through stepwise model selection, from the simplest model to more
189 complex ones using the information index Deviance Information Criterion (DIC) as an
190 acceptance/reject rule for the proposed models, if a proposed model had lower DIC than the

191 currently accepted model, it was accepted, otherwise it was rejected. The procedure was
192 repeated until the DIC began to increase.

193

194 **2.7.1. Proposed models for Enteropooling and Motility:**

195 *Step 1:*

196 Null model: composed only of mean and error, in which the mean and error were assumed
197 constant for all the individuals used and treatments applied, analogous to the null
198 hypothesis in frequentist statistical approach. Two parameters.

199 *Step 2:*

200 Time Effect: The motility changed with time. Four parameters.

201 ITX Treatment Effect: The response variable changed with the addition of ITX. Three
202 parameters.

203 *Step 3 (proposed in case of acceptance of Step 2 models):*

204 Time + ITX Effect: Additive effect of both treatments. Five parameters.

205 *Step 4 (proposed in case of acceptance of Step 3 models):*

206 Time + ITX Effect plus interaction term: Additive effect of both treatments plus a
207 multiplicative interaction term. Six parameters.

208 **2.7.2. Proposed models for loops:**

209 *Step 1:*

210 Null Model: Similar to the previous one. Two parameters.

211 *Step 2:*

212 Treatment effect: The response variable changed with the addition of the treatment,
213 independently of the concentration. Three parameters.

214 Treatment effect 2: The response variable changed with the addition of the treatment, and
215 with different concentration. Four parameters.

216 Linear Treatment effect: The response variable changed as a linear function of the
217 concentration of the treatment. Three parameters.

218 **2.7.3. Fitting:**

219 In the case of Motility the variable measured was a proportion, so the data was logit-
220 transformed in order to use a normal-likelihood function to fit the models. For
221 enteropooling and loops we used directly a normal likelihood function. Normal distribution
222 with mean zero and ten standard deviation was used as an uninformative prior distribution
223 for all the estimated parameters. A posteriori distribution of the parameters and the DIC
224 index were calculated using the PyMC Markov-Chain Monte Carlo (MCMC) toolkit for the
225 Python programming language [21]. Models were run for 200 000 iterations with a 100 000
226 iteration discarded as a burn-in period and the second 100 000 were used to calculate the
227 posterior distribution of parameters. We evaluated model convergence using Geweke's
228 method.

229

230

231 **3. Results.**

232

233 **3.1. ITX induces lethality in mice:**

234 Mice were i. g. or i. v. challenged with 200 U, 100 U or 50 U of ITX (1 $\mu\text{g/ml}$ Ia + 2 $\mu\text{g/ml}$
235 Ib, 0.5 $\mu\text{g/ml}$ Ia + 1 $\mu\text{g/ml}$ Ib, 0.25 $\mu\text{g/ml}$ Ia + 0.5 $\mu\text{g/ml}$ Ib, respectively). The proposed
236 model for ITX effect with lower DIC was the Null Model (DIC = 43.02), whereas the other
237 proposed models in the stepwise procedure had higher DIC values (time effect DIC =

238 43.22, and ITX Treatment Effect DIC = 45.03). Therefore, ITX i. g. administration did not
239 produce significant changes in survival times or signs of illness in any of the concentrations
240 tested. Intravenous administration of 100 U and 50 U of ITX did not produce significant
241 changes in survival times or signs of illness. When mice were inoculated i. v. with 200 U of
242 ITX, onset of clinical manifestations (respiratory distress and depression) occurred within
243 the first 6 h. In this group, the average time from inoculation to assay end point was 30 ± 10
244 h. The intravenous LD₅₀ of the ITX was determined to be 1 µg/ml of Ia + 2 µg/ml of Ib per
245 mouse.

246

247 **3.2. Gross pathology and histological analysis:**

248 ITX treated ileal loops showed grossly red mucosa with thick, mucoid and red content, all
249 of which could be observed from the serosal surface. The intestinal wall appeared thin and
250 lost natural tone. A relatively low fluid accumulation was observed and the intestinal fluid
251 became progressively bloodier as the ITX doses increased. Histological examination
252 revealed that a 4 h treatment with ITX caused clear damage to mucosal epithelium and the
253 severity and extent of this ITX-induced damage showed a dose dependency in ileal loops.
254 Treatment of loops with 200 U/ml of ITX resulted in a severe necrosis of the intestinal
255 epithelium with blunting and fusion of intestinal villi, extensive pseudomembrane
256 formation with polymorphonuclear infiltration in the lumen and mucosa (Fig.1).
257 Morphologic changes in loops treated with 100 U/ml of ITX include mild shortening of the
258 villi with degenerative changes in enterocytes on the tip and center of the villi. Mild
259 polymorphonuclear infiltrate and edema was also observed in the lamina propria and
260 submucosa (Fig.1). These changes were not observed in the control ileal loops (Fig.1) or in
261 loops exposed to purified ITX pre-incubated with one of two different neutralizing anti-ITX

262 antibodies, which totally abolished the ability of ITX to cause histological damage (data not
263 shown). These results show that ITX was the active agent producing the intestinal damage
264 described above. In contrast, no histologic damage was observed when the colon was
265 treated with ITX (100 or 200 U/ml). After 4 h of treatment with ITX, the colon appeared
266 similar to the control colon treated only with Ringer's solution. Together, these results
267 indicated that purified ITX causes histologic damage in mouse small intestine but not in the
268 colon, at least under the experimental conditions used in the present study.

269

270 **3.3. Intestinal ITX binding:**

271 ITX was injected into intestinal loops of mice and toxin binding was analyzed by indirect
272 IHC. In ITX treated ileal loops, it was possible to observe extensive binding of toxin
273 throughout the entire mucosa. Specific binding to mucosal epithelial cells was limited to the
274 brush border; the cytoplasm and nuclei of labeled cells were unstained (Fig.2). Brush
275 border binding was differentiable from any edge effect because individual cells exhibited
276 intense staining while rare cells in the midst of positively stained cells were negative.
277 Binding was observed at the tip, center and base of the villi. Crypt cells were also stained,
278 but binding in the crypts was moderate compared with villi. No staining was detected in
279 any ileum control loop (Fig.2) or colon loops, either treated or control.

280

281 **3.4. Effects of ITX on intestinal fluid accumulation:**

282 The effects of ITX in the fluid homeostasis of the intestine were initially determined by the
283 enteropooling assay in mice. After i. g. challenge with 200 U/ml of purified ITX, no
284 significant differences were observed when compared to the control group at 6 h (6.14 vs.
285 6.92 mg/cm) and 20 h (9.78 vs. 9.72 mg/cm). The effects of ITX on intestinal fluid

286 accumulation were also evaluated in ligated ileal loops with 200 and 100 U/ml of purified
287 ITX. Of the proposed models for loops, the lower DIC value was corresponding to Linear
288 treatment effect (DIC = 52.73), whereas the other proposed models had higher DIC (Null
289 Model, DIC = 53.54, Treatment Effect DIC = 54.12, Treatment Effect 2 DIC = 54.62).
290 Therefore we found that increased fluid accumulation was observed in ITX treated loops,
291 and it was linearly dependent on toxin concentration (Fig.3), with a slope of 0.016 +/- 0.01,
292 and the intercept 0.77 +/- 0.516. Intestinal fluid accumulation was increased by 3 and 5-fold
293 respect to control intestines after 4 h of treatment with 100 U and 200 U ITX, respectively.

294

295 **3.5. Effect of ITX on gastrointestinal transit:**

296 The charcoal meal method was used to test if i. g. delivered ITX inhibits intestinal motility.
297 Administration of 200 U/ml of ITX had no effect on the luminal movement of the marker
298 (charcoal), expressed as a percentage of the total length of the small intestine from the
299 pylorus to caecum, when compared with the control group (data not shown).

300

301

302 **4. Discussion**

303

304 Iota toxin and infection by *C. perfringens* type E strains are associated with sudden death
305 and hemorrhagic enteritis in different animal species [2–5]. Although ITX production is
306 limited to type E strains, structurally related binary toxins are widely spread among other
307 species of enterotoxic clostridia and *Bacillus* [22]. Based on sequence homology,
308 immunological cross-reactivity and biologically active chimeras formation, clostridial
309 binary toxins are classified in two families, the iota family and the C2 family [23]. Besides

310 ITX, the iota-family also includes *C. difficile* CDT and *C. spiroforme* CST [23]. These
311 toxins not only share structure and sequence homology but might also share biological
312 functions such as the observed strain specific increase of intestinal attachment of *C.*
313 *perfringens* bacterial cells [17] in other clostridial species including *C. difficile* [24].
314 Although cellular intoxication by ITX and binary toxins has been extensively studied
315 [9,11–13], there is scant information about intestinal alterations induced by binary toxins
316 and their role in digestive diseases, usually limited to descriptions of natural cases [2–4,25].
317 In the present report, mice were used as animal model to study the effects of ITX in the
318 gastrointestinal tract. According to previous studies, mice are sensitive to ITX [26] and
319 provide several advantages over other species as model given its small size and wide
320 availability [27–29]. The LD₅₀ for i. v. ITX was in agreement with previous reports [14,30],
321 which is a relatively high LD₅₀ (above 1 µg/mouse) compared to other toxins that produce
322 enterotoxemia (i.e. epsilon toxin, 3 ng/mouse), raising questions about the role of ITX in
323 clinical signs and systemic changes described in natural cases of type E disease, usually
324 defined as type E or iota enterotoxemia [3].
325 Several reports of disease associated with *C. perfringens* type E in cattle show that the
326 dominant necropsy finding is hemorrhagic enteritis affecting jejunum and ileum [3,4], and
327 severe necrosis of the mucosal epithelium as the main microscopic lesions of the small
328 intestine. The histopathological findings of the present study are consistent with those
329 described in natural cases of cattle type E enteritis [3,4]. Intraintestinal inoculation of
330 purified ITX in ileal ligated loops of mice reproduced microscopic changes in a dose-
331 dependent manner, which could be prevented using anti-ITX neutralizing antibodies.
332 The development of progressive microscopic lesions with increasing ITX concentrations
333 provides new insights into the pathogenesis of type E diseases. First, treatment of ligated

334 ileal loop with a low toxin concentration causes necrosis of enterocytes at the tip of the villi
335 and degenerative changes in the enterocytes of the middle region of the villi. These
336 conditions may represent those present at the onset of the disease, where the first cells to be
337 affected seem to be enterocytes of the tip of the villus. With a higher concentration of toxin,
338 it is possible to observe mucosa areas with completely detached epithelium, which can also
339 be considered as a progression of the action of lower concentrations of toxin. Also,
340 coincident with reports of type E disease in ruminants, mice challenged with ITX did not
341 develop alterations in the large intestine after intragastric and colonic loops challenge.

342 Although *C. perfringens* type E infection is generally associated with sudden death, some
343 reports describe the occurrence of diarrhea in cattle [3,6]. Previous *in-vitro* and *in-vivo*
344 studies suggest that ITX can have a key role in alterations of intestinal fluid homeostasis.
345 *In-vitro* studies show that ITX can induce permeability changes in Caco-2 cells monolayers
346 [15]. *In-vivo* studies with other clostridial binary toxins, like CDT from *C. difficile* [31,32]
347 and BEC from *C. perfringens* [33,34], also described fluid accumulation in the intestinal
348 lumen. In the present report, fluid imbalance was determined by two different approaches,
349 enteropooling and intestinal loops. Although the enteropooling technique estimates the net
350 movement of fluid through the intestinal wall [18], the differences in fluid accumulated in
351 the small intestine after treatment with ITX were not statistically significant. . It was
352 possible to observe a statistically significant increase in liquid accumulation in a dose
353 dependent manner when ligated ileal loops were used. These results suggest an enterotoxic
354 action of ITX and reinforce the concept that binary toxins could share biological effects.

355 For example, as while *C. difficile* infection in most species is considered a large bowel
356 disease, strains producing only CDT induce fluid accumulation in ileum as it was observed
357 using different animal models like rabbit [32] or golden hamster [31].

358 Histopathology analysis of treated loops showed that ITX causes degenerative changes and
359 necrosis of small intestinal enterocytes, suggesting that fluid accumulation could be
360 associated with loss of intestinal epithelial barrier integrity. Apical and lateral region of the
361 villi were the most affected areas, and a functional decrease of these enterocytes, which are
362 primarily responsible for the absorption of water, would lead to a net increase in the amount
363 of liquid present in the intestinal lumen. Higher concentrations of ITX induce epithelium
364 detachment with the concomitant fluid passage from blood and lymph to intestinal lumen.
365 Since gastrointestinal motility disturbances is an important mechanism involved in digestive
366 disorders, ITX effect upon intestinal motility was measured by intestinal dye retention, a
367 method widely used in different studies [19]. No differences were observed between ITX
368 treated animals and controls, suggesting that ITX has no effect on gastrointestinal motility.
369 However, further studies with different approaches would be necessary to confirm this
370 result.

371 The present study shows that ITX produces intestinal damage consistent with lesions
372 observed in natural cases of type E enteritis. Therefore, it is possible to propose a central
373 role for ITX in *C. perfringens* type E pathogenesis and probably for other binary toxins in
374 determined diseases like CDT in *C. difficile* enteritis and, eventually, colitis. According to
375 our findings, changes in mucosal epithelium could be one of the main mechanisms
376 involved in type E pathogenesis. The current study serves as a starting point to propose
377 potential mechanisms involved in initial stages of *C. perfringens* type E pathogenesis.

378

379 **Competing Interests:**

380 The authors have declared that no competing interests exist.

381

382 **Acknowledgments:**

383 This research was supported by Instituto Nacional de Tecnología Agropecuaria Grant
384 INTA PNBIO-115052. We also thank the Consejo Nacional de Investigaciones Científicas y
385 Tecnológicas - Argentina for support. We thank, Ms. Laura Gonzales, Ms. Jesica S. Bucci,
386 Mr. Daniel Funes and Ms. Claudia Moreno for invaluable help at the lab. We thank Ms.
387 Daniela Losada Eaton for her manuscript correction.

388

389 **References:**

- 390 [1] T.J. Bosworth, On a new type of toxin produced by *Clostridium welchii*, J. Comp.
391 Pathol. Ther. 53 (1943) 245–255. doi:10.1016/S0368-1742(43)80024-2.
- 392 [2] B. Hart, P.T. Hooper, Enterotoxaemia of calves due to *Clostridium welchii* type E,
393 Aust. Vet. J. 43 (1967). doi:10.1017/CBO9781107415324.004.
- 394 [3] J.G. Songer, D.W. Miskimmins, *Clostridium perfringens* type E enteritis in calves:
395 Two cases and a brief review of the literature, Anaerobe. 10 (2004) 239–242.
396 doi:10.1016/j.anaerobe.2004.05.001.
- 397 [4] L.M. Redondo, M. Farber, A. Venzano, H. Jost, Y.R.. Parma, M.E. Fernández-
398 Miyakawa, Sudden death syndrome in adult cows associated with *Clostridium*
399 *perfringens* type E, Anaerobe. 20 (2013) 1–4.
- 400 [5] B. McClane, F. Uzal, M. Fernandez Miyakawa, D. Lyerly, T. Wilkins, The
401 enterotoxic clostridia, in: Dworkin, M., Falkow, S., Rosenberg, E., Schlefer, K. H.,

- 402 Stackebrant, E. (Eds.), *The Prokaryotes*, Springer science, New York, 2006, pp. 698-
403 752. doi:10.1007/0-387-30744-3_22.
- 404 [6] H.Y. Kim, J.W. Byun, I.S. Roh, Y.C. Bae, M.H. Lee, B. Kim, J.G. Songer, B.Y.
405 Jung, First isolation of *Clostridium perfringens* type E from a goat with diarrhea,
406 *Anaerobe*. 22 (2013) 141–143. doi:10.1016/j.anaerobe.2013.06.009.
- 407 [7] M.C. Ferrarezi, T.C. Cardoso, I.S. Dutra, Genotyping of *Clostridium perfringens*
408 isolated from calves with neonatal diarrhea., *Anaerobe*. 14 (2008) 328–31.
409 doi:10.1016/j.anaerobe.2008.12.001.
- 410 [8] S.P. Borriello, R.J. Carman, Association of iota-like toxin and *Clostridium*
411 *spiroforme* with both spontaneous and antibiotic-associated diarrhea and colitis in
412 rabbits, *J. Clin. Microbiol.* 17 (1983) 414–418.
- 413 [9] H. Barth, K. Aktories, M. Popoff, B.G. Stiles, Binary bacterial toxins: biochemistry,
414 biology, and applications of common *Clostridium* and *Bacillus* proteins, *Microbiol.*
415 *Mol. Biol. Rev.* 68 (2004) 373–402. doi:10.1128/MMBR.68.3.373.
- 416 [10] B.G. Stiles, K. Pradhan, J.M. Fleming, R.P. erumal Samy, H. Barth, M.R. Popoff,
417 *Clostridium* and *Bacillus* binary enterotoxins: bad for the bowels, and eukaryotic
418 being, *Toxins (Basel)*. 6 (2014) 2626–2656. doi:10.3390/toxins6092626.
- 419 [11] P. Papatheodorou, J.E. Carette, G.W. Bell, C. Schwan, G. Guttenberg, T.R.
420 Brummelkamp, K. Aktories, Lipolysis-stimulated lipoprotein receptor (LSR) is the
421 host receptor for the binary toxin *Clostridium difficile* transferase (CDT)., *Proc. Natl.*
422 *Acad. Sci. U. S. A.* 108 (2011) 16422–7. doi:10.1073/pnas.1109772108.

- 423 [12] P. Papatheodorou, C. Wilczek, T. Nölke, G. Guttenberg, D. Hornuss, C. Schwan, K.
424 Aktories, Identification of the cellular receptor of *Clostridium spiroforme* toxin,
425 Infect. Immun. 80 (2012) 1418–1423. doi:10.1128/IAI.06378-11.
- 426 [13] J. Sakurai, M. Nagahama, M. Oda, H. Tsuge, K. Kobayashi, *Clostridium perfringens*
427 iota-toxin: structure and function., Toxins (Basel). 1 (2009) 208–28.
428 doi:10.3390/toxins1020208.
- 429 [14] B.G. Stiles, T.D. Wilkins, Purification and characterization of *Clostridium*
430 *perfringens* iota toxin: Dependence on two nonlinked proteins for biological activity,
431 Infect. Immun. 54 (1986) 683–688.
- 432 [15] J.F. Richard, G. Mainguy, M. Gibert, J.C. Marvaud, B.G. Stiles, M.R. Popoff,
433 Transcytosis of iota-toxin across polarized CaCo-2 cells, Mol. Microbiol. 43 (2002)
434 907–917. doi:10.1046/j.1365-2958.2002.02806.x.
- 435 [16] L.J. Reed, H. Muench, A simple method of estimating fifty per cent endpoint., Am.
436 J. Hyg. 27 (1938) 493–497.
- 437 [17] L.M. Redondo, J.M. Diaz Carrasco, E.A. Redondo, F. Delgado, M.E. Fernández-
438 Miyakawa, *Clostridium perfringens* type E virulence traits involved in gut
439 colonization, PLoS One. 10 (2015) 1–18. doi:10.1371/journal.pone.0121305.
- 440 [18] J. Goldstein, W.E. Morris, C.F. Loidi, C. Tironi-Farinatti, B.A. McClane, F.A. Uzal,
441 M.E. Fernandez-Miyakawa, *Clostridium perfringens* epsilon toxin increases the
442 small intestinal permeability in mice and rats, PLoS One. 4 (2009).
443 doi:10.1371/journal.pone.0007065.

- 444 [19] D.M. Losada-Eaton, M.E. Fernandez-Miyakawa, *Clostridium perfringens* epsilon
445 toxin inhibits the gastrointestinal transit in mice, *Res. Vet. Sci.* 89 (2010) 404–408.
446 doi:10.1016/j.rvsc.2010.04.006.
- 447 [20] A. Gelman, A bayesian formulation of exploratory data analysis and goodness-of-fit
448 testing *, *Int. Stat. Rev.* 71 (2003) 369–382. doi:10.1111/j.1751-
449 5823.2003.tb00203.x.
- 450 [21] A. Patil, D. Huard, C. J. Fonnesbeck, PyMC : Bayesian stochastic modelling in
451 Python, *J Stat Softw.* 35 (2011) 1–81.
- 452 [22] B.G. Stiles, H. Barth, M.R. Popoff, *Clostridium perfringens* iota toxin: A
453 successfully shared template for common enteric pathogens, in: Gopalakrishnakone,
454 P., Stiles, B., Alape-Grion, A., Dubreuil, J.D., Mandal, M. (Eds.), *Microbial Toxins*,
455 Springer science, New York, 2016: pp. 1–20. doi:10.1007/978-94-007-6725-6.
- 456 [23] B.G. Stiles, D.J. Wigelsworth, M.R. Popoff, H. Barth, Clostridial binary toxins: iota
457 and C2 family portraits, *Front. Cell. Infect. Microbiol.* 1 (2011) 1–14.
458 doi:10.3389/fcimb.2011.00011.
- 459 [24] C. Schwan, B. Stecher, T. Tzivelekidis, M. Van Ham, M. Rohde, W.D. Hardt, J.
460 Wehland, K. Aktories, *Clostridium difficile* toxin CDT induces formation of
461 microtubule-based protrusions and increases adherence of bacteria, *PLoS Pathog.* 5
462 (2009). doi:10.1371/journal.ppat.1000626.
- 463 [25] D.N. Gerding, S. Johnson, M. Rupnik, K. Aktories, *Clostridium difficile* binary toxin
464 CDT: mechanism, epidemiology, and potential clinical importance, *Gut Microbes.* 5

- 465 (2014) 15–27. doi:10.4161/gmic.26854.
- 466 [26] L.L. Simpson, B.G. Stiles, H.H. Zepeda, T.D. Wilkins, Molecular basis for the
467 pathological actions of *Clostridium perfringens* iota toxin., *Infect. Immun.* 55 (1987)
468 118–22.
- 469 [27] F.A. Uzal, J. Saputo, S. Sayeed, J.E. Vidal, D.J. Fisher, R. Poon, V. Adams, M.E.
470 Fernandez-Miyakawa, J.I. Rood, B.A. McClane, Development and application of
471 new mouse models to study the pathogenesis of *Clostridium perfringens* type C
472 enterotoxemias, *Infect. Immun.* 77 (2009) 5291–5299. doi:10.1128/IAI.00825-09.
- 473 [28] M.E. Fernandez-Miyakawa, S. Sayeed, D.J. Fisher, R. Poon, V. Adams, J.I. Rood,
474 B.A. McClane, J. Saputo, F. a Uzal, Development and application of an oral
475 challenge mouse model for studying *Clostridium perfringens* type D infection.,
476 *Infect. Immun.* 75 (2007) 4282–8. doi:10.1128/IAI.00562-07.
- 477 [29] J.A. Caserta, S.L. Robertson, J. Saputo, A. Shrestha, B.A. McClane, F.A. Uzal,
478 Development and application of a mouse intestinal loop model to study the in vivo
479 action of *Clostridium perfringens* enterotoxin, *Infect. Immun.* 79 (2011) 3020–3027.
480 doi:10.1128/IAI.01342-10.
- 481 [30] C.L. Hatheway, Toxigenic clostridia, *Clin. Microbiol. Rev.* 3 (1990) 66–98.
482 doi:10.1128/CMR.3.1.66.Updated.
- 483 [31] S.A. Kuehne, M.M. Collery, M.L. Kelly, S.T. Cartman, A. Cockayne, N.P. Minton,
484 Importance of toxin a, toxin b, and cdt in virulence of an epidemic *Clostridium*
485 *difficile* strain, *J. Infect. Dis.* 209 (2014) 83–86. doi:10.1093/infdis/jit426.

- 486 [32] B. Geric, R.J. Carman, M. Rupnik, C.W. Genheimer, S.P. Sambol, D.M. Lysterly,
487 D.N. Gerding, S. Johnson, Binary toxin-producing, large clostridial toxin-negative
488 *Clostridium difficile* strains are enterotoxic but do not cause disease in hamsters., J.
489 Infect. Dis. 193 (2006) 1143–50. doi:10.1086/501368.
- 490 [33] S. Yonogi, S. Matsuda, T. Kawai, T. Yoda, T. Harada, Y. Kumeda, K. Gotoh, H.
491 Hiyoshi, S. Nakamura, T. Kodama, T. Iida, BEC, a novel enterotoxin of *Clostridium*
492 *perfringens* found in human clinical isolates from acute gastroenteritis outbreaks,
493 Infect. Immun. 82 (2014) 2390–2399. doi:10.1128/IAI.01759-14.
- 494 [34] D. Irikura, C. Monma, Y. Suzuki, A. Nakama, A. Kai, A. Fukui-Miyazaki, Y.
495 Horiguchi, T. Yoshinari, Y. Sugita-Konishi, Y. Kamata, Identification and
496 characterization of a new enterotoxin produced by *Clostridium perfringens* isolated
497 from food poisoning outbreaks, PLoS One. 10 (2015) 1–25.
498 doi:10.1371/journal.pone.0138183.

499

500


501 **Figure legends**

502 **Fig 1:** Histology of ITX treated small intestine loops. After 4 h of treatment, loop tissues
503 were formalin fixed and embedded in paraffin. H/E was used to stain 4 μ m-thick sections of
504 intestinal tissue. Control loops (A). Loops treated with 100 U/ml (B) and 200 U/ml (C) of
505 purified ITX. Scale bar, 100 μ m.


506 **Fig 2:** Immunohistochemistry of ITX treated small intestine. (A) Sections of intestinal
507 tissue treated with control buffer. (B) Sections of intestinal tissue treated with 100 U/ml of
508 purified ITX. In ITX treated loops the brush border is variably labeled with dense staining
509 of individual cells adjacent to cells not stained (arrows). Scale bar, 20 μ m.


510 **Fig 3:** ITX alters fluid homeostasis in the small intestine. Ligated ileal segments (loops)
511 were excised 4 hours after injection of ITX and intestinal water was determined. Data
512 shown are mean values obtained by using 4 mice (1 ileal loop/mouse). Error bars represent
513 the SEM. Results are expressed as means \pm SEM based on data from 4 loops for each ITX
514 dose.

515



ACCEPTED MANUSCRIPT





ACCEPTED MANUSCRIPT

Highlights:

1. Iota toxin intestinal effects were evaluated in a mouse model.
2. Iota toxin causes histological damage in mouse ileal loops.
3. Luminal iota toxin induced fluid accumulation in the small intestine.
4. Mice are sensitive to intravenously administered iota toxin.